Dextromethorphan Combinations Using CYP2D6 Inhibition for Sustained Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for neurological and psychiatric conditions, particularly those involving dextromethorphan, face challenges such as rapid metabolism leading to low plasma levels and adverse events, necessitating frequent dosing and loss of efficacy.
Innovation Solution
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to enhance plasma levels, inhibit metabolism, and reduce adverse events, using sustained release delivery systems and specific dosing regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dextromethorphan is administered alone, then it provides therapeutic effect for neurological and psychiatric conditions, but rapid metabolism leads to low plasma levels and loss of efficacy
Solution Approach 1:
The patent uses CYP2D6 inhibitor compounds as intermediary substances that block the metabolic pathway of dextromethorphan. By introducing this mediator compound, the rapid metabolism problem is resolved without directly modifying dextromethorphan itself, allowing sustained plasma levels through pharmacokinetic interaction
Solution Approach 2:
The patent changes the metabolic parameter of dextromethorphan by co-administering CYP2D6 inhibitors. This alters the elimination rate constant and half-life of dextromethorphan, transforming its pharmacokinetic profile from rapid clearance to sustained presence in plasma
2Reliability
If dextromethorphan is administered alone, then it treats neurological conditions, but frequent dosing is required due to rapid metabolism
Solution Approach 1:
By introducing CYP2D6 inhibitor compounds as mediators, the system transforms the dosing paradigm from frequent administration of dextromethorphan alone to less frequent co-administration of the inhibitor combination, reducing burden while maintaining efficacy
3Reliability
If dextromethorphan is administered at higher doses to maintain plasma levels, then therapeutic effect is improved, but adverse events increase
Solution Approach 1:
The patent changes the dosing parameter from high single doses of dextromethorphan to lower combined doses of dextromethorphan plus CYP2D6 inhibitor. This parameter transformation maintains plasma levels while reducing peak concentrations that cause adverse events
4Reliability
If dextromethorphan is administered to extensive metabolizers, then it provides initial therapeutic effect, but metabolism is too rapid for sustained efficacy
Solution Approach 1:
The patent introduces CYP2D6 inhibitor compounds as intermediaries specifically for extensive metabolizers. These inhibitors selectively block the overactive metabolic pathway in this population, extending the metabolic lifetime of dextromethorphan without affecting poor metabolizers who already have prolonged drug presence
Data Source
AI summary
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.